Wuhan Institute of Biological Products
 | You can help expand this article with text translated from the corresponding article in Chinese. (August 2021) Click [show] for important translation instructions.
|
The Wuhan Institute of Biological Products (WIBP Chinese: 武汉生物制品研究所) or Wuhan Institute of Biology for short is a subsidiary of China National Pharmaceutical Group, a Chinese state-owned enterprise commonly known as Sinopharm.[1] The institute integrates production, education, research, and marketing, and operates one of the main production facilities for biological products in China, with over 1,000 employees. The commercial arm of the institute operates a wholly owned subsidiary called Wuhan Zhongsheng Yujin Biomedical, which is primarily focused on the production distribution of blood products including human albumin, human immune globulin and tetanus immune globulin. The educational arm of the institute confers Master's degrees and runs doctoral and postdoctoral programs in biotechnology related fields. The institute was established in September 1950 in Wuchang District, moving in 2016 to the Zhengdian Gold Industrial Park in Jiangxia District, next to the Wuhan Institute of Virology, with which it collaborates closely.[2][3]
Divisions[edit]
National Engineering Technology Research Center for Combined Vaccines[citation needed]
See also[edit]
References[edit]
- ^ "Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 bln doses". Reuters. June 1, 2021.
- ^ Philippidis, Alex (May 18, 2020). "Sinopharm Group (Wuhan Institute of Biological Products) and Chinese Academy of Sciences (Wuhan Institute of Virology)".
- ^ "Two COVID-19 vaccines approved in China in less than 24 hours". www.bioworld.com.
External links[edit]
 | This China-related article is a stub. You can help Wikipedia by expanding it. |